These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1493 related articles for article (PubMed ID: 31835042)

  • 21. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Al-Ahmadi A; Ardeshir-Larijani F; Fu P; Cao S; Lipka MB; Dowlati A; Bruno DS
    Clin Lung Cancer; 2021 Jan; 22(1):16-22.e1. PubMed ID: 33397584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
    Kuang S; Fung AS; Perdrizet KA; Chen K; Li JJN; Le LW; Cabanero M; Karsaneh OAA; Tsao MS; Morganstein J; Ranich L; Smith AC; Wei C; Cheung C; Shepherd FA; Liu G; Bradbury P; Pal P; Schwock J; Sacher AG; Law JH; Stockley TL; Leighl NB
    Curr Oncol; 2022 Jun; 29(7):4428-4437. PubMed ID: 35877212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.
    Nassereddine H; Sannier A; Brosseau S; Rodier JM; Khalil A; Msika S; Danel C; Couvelard A; Théou-Anton N; Cazes A
    Pathol Oncol Res; 2020 Oct; 26(4):2795-2800. PubMed ID: 31407221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
    Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
    BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
    Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
    Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A; Grosse C; Rechsteiner M; Soltermann A
    Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
    Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
    Dalal AA; Guerin A; Mutebi A; Culver KW
    J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation Spectrum of
    Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
    Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.